There is a period that the patent holder has exclusive on the product, but it's from the date of patent issue and not production. After that, generics kick in with no compensation.
North County Clinical Research ( http://ih.advfn.com/p.php?pid=nmona&article=61887961 ) looks OK, but small. What BioRegenerative Sciences has to offer is IMHO, questionable. My brief research on them shows them to be like a hair club for women. Not sure how they would fit in.
The oil and gas PR's are over the top. The supply is tightly controlled as are all form of distribution. Contracts are generally long term and buyers stick to reputable suppliers to ensure continued supply. This company doesn't have the funds to deal in that sector. The 50m funding from the bone cruncher wouldn't be enough to start.
PR's like the oil one don't work anymore. That may have caused a run 10 years ago, but investors are getting smarter.
It really doesn't help that the company has a history of failure and a rising OS. Those 144 filings don't help either.